Good points Captain.
As an aside, I think possibly the best thing about today’s presentation at Rhode Island hospital by participating neurosurgeons was the sincerity and objective reflection on the advance. Wherein, it requires a nuanced understanding of how “breakthrough” is defined.
A patient wants to know if they can “beat” this. Because DCVax-l in some cases can restore a functioning immune system, facilitate detection and destruction of the cancer and alertness to further cloaked attacks, it is the closest therapy patients have to “beat” GBM in some cases.
If approved, because of the requirements for combination therapies, as LP further explained recently, it can then be combined with other therapies like CSF1R, that remove tolerogenic cells from the tumor micro-environment, thus making recurrence far less likely. Aka: More cures.
LP really did recently try to subtly answer why combinations face more than just resource issues for trials. They also face dysfunctional regulators that can’t imagine two therapies might work together where only one by itself can on a limited basis. It’s as if the FDA would say iron makers can’t commercialize steel because carbon doesn’t make metal by itself.
Anyway, I digress.
Market Data 
Markets 
AI
